Pneumologie 2015; 69 - A62
DOI: 10.1055/s-0035-1556654

6 years of Certified Lung Cancer Center – The Heidelberg Experience

T Muley 1, 2, S Kobinger 1, D Firnkorn 3, H Dienemann 1, 2, H Hoffmann 1, M Thomas 1, 2, FJ Herth 1, 2, CP Heussel 1, 2, A Warth 2, 4, J Kappes 1
  • 1Thoraxklinik am Universitätsklinikum Heidelberg
  • 2TLRC Heidelberg, member of the German Center for Lung Research (DZL)
  • 3Institut für Medizinische Biometrie und Informatik, Universität Heidelberg
  • 4Pathologisches Institut, Universität Heidelberg

A clinical registry is required to document treatment results of primary lung cancer patients treated in certified lung cancer centers. The results have to be analyzed yearly and presented to dedicated external auditors.

5332 primary lung cancer patients were diagnosed and treated at our institution between 2009 and 2014. There were 873 SCLC, 4347 NSCLC, 104 carcinoids and 8 mucoepidermoidal carcinomas. Within NSCLC adenocarinoma (n = 2536) was the largest subgroup followed by squamous cell (n = 1233), NSCLC nos (218), large cell carcinoma (n = 165), NSCLC mixed subtypes (n = 154) and pleomorphic/sarcomatoid carcinoma (n = 41).

The 5-years survival rate was 24.3% and the median survival (MS) was 16.5 months. The median follow-up time was 27.2 months. The mean follow-up rate of patients was 95.5%. The lymph node status was an important factor influencing long term survival (MS: cN0 = 66.7mos, cN1 = 20.4mos, cN2 = 12.7 and cN3 = 8.1mos). The MS for clinical stages was not reached in Ia, 66.7 mos in Ib, not reached in IIa, 38.3 mos in IIb, 24.3 mos in IIIa 14.6 mos in IIIb, 12.7 mos in IVa and 7.2 mos in IVb. In regard to metastatic status MS was 38.0 mos (cM0), 12.7 mos (cM1a) and 7.3 mos (cM1b), respectively. Differences in major metastatic sites were found for histological subtypes of oncological patients. In squamous cell carcinoma the major site was the lung (26.8%) followed by bone (20.2%). In adenocarcinoma bone (45%), lung (38.8%) and brain (35.3%) metastases were found most frequently. In SCLC metastases in liver (43.1%) were followed by brain (34.5%) and bone (32.6%).

Our clinical lung cancer registry proved to be a powerful tool for analyzing treatment results in lung cancer. However, frequent analyses are necessary to constantly improve documentation and data quality in order to detect clues for improvement of therapeutic strategies.

*Presenting author